(IBTK) iShares iBonds Dec 2030 - Ratings and Ratios
Treasury Bonds, Cash Equivalents, Money Market
Description: IBTK iShares iBonds Dec 2030 October 25, 2025
The iShares iBonds Dec 2030 Term Treasury ETF (IBTK) tracks the ICE 2030 Maturity U.S. Treasury Index, holding publicly-issued U.S. Treasury securities that mature between 1 Jan 2030 and 15 Dec 2030. The fund may also allocate a modest portion to short-term paper, cash, and money-market shares to manage liquidity.
Key metrics as of the latest reporting period: expense ratio ≈ 0.20 %, weighted-average maturity ≈ 2030, and a 30-day SEC yield around 4.3 % (reflecting the current 10-year Treasury rate). The ETF’s performance is highly sensitive to Federal Reserve policy-particularly changes in short-term rates and the shape of the yield curve-as well as fiscal-deficit dynamics that influence Treasury issuance volumes.
For a deeper dive into how IBTK fits into a broader portfolio, you might explore the analytics on ValueRay.
IBTK ETF Overview
| Market Cap in USD | 566m |
| Category | Target Maturity |
| TER | 0.07% |
| IPO / Inception | 2020-07-14 |
IBTK ETF Ratings
| Growth Rating | 51.0% |
| Fundamental | - |
| Dividend Rating | 76.1% |
| Return 12m vs S&P 500 | -11.3% |
| Analyst Rating | - |
IBTK Dividends
| Dividend Yield 12m | 3.82% |
| Yield on Cost 5y | 3.52% |
| Annual Growth 5y | 85.27% |
| Payout Consistency | 100.0% |
| Payout Ratio | % |
IBTK Growth Ratios
| Growth Correlation 3m | 83.3% |
| Growth Correlation 12m | 96.1% |
| Growth Correlation 5y | -0.2% |
| CAGR 5y | 4.90% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.58 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.17 |
| Sharpe Ratio 12m | -0.99 |
| Alpha | -13.31 |
| Beta | 0.970 |
| Volatility | 3.12% |
| Current Volume | 102.8k |
| Average Volume 20d | 108.3k |
| Stop Loss | 19.2 (-3.3%) |
| Signal | 0.44 |
What is the price of IBTK shares?
Over the past week, the price has changed by -0.28%, over one month by +0.52%, over three months by +1.16% and over the past year by +6.37%.
Is iShares iBonds Dec 2030 a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IBTK is around 19.10 USD . This means that IBTK is currently overvalued and has a potential downside of -3.83%.
Is IBTK a buy, sell or hold?
What are the forecasts/targets for the IBTK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 21.5 | 8.3% |
IBTK Fundamental Data Overview November 04, 2025
Beta = 0.97
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 566.1m USD (566.1m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 566.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 566.1m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.59% (E(566.1m)/V(566.1m) * Re(9.59%) + (debt-free company))
Discount Rate = 9.59% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for IBTK ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle